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Abstract 
Ethnopharmacological relevance:  
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Derris scandens (Roxb.) Benth. has been used as active ingredient in Thai traditional 
medicine recipes for pain treatment. Dry stem powder and ethanolic extract also 
recommended in Thailand National List of Essential Medicines (NLEMs) for musculoskeletal 
pain treatment as herbal medicine. However, no summarization of clinical effect and safety 
has been evaluated. 
Objective 
Our study aimed to determine the clinical effects and safety of D. scandens for 
musculoskeletal pain treatment compared with standard regimen,nonsteroidal anti-
inflammatory drugs (NSAIDs). 
Methods 
International and Thai databases were searched from inception through August 2015. 
Comparative randomized controlled trials investigating oral D. scandens for musculoskeletal 
pain were included. Outcomes of interest included level of pain and adverse event. Mean 
changes of the outcomes from baseline were compared between D. scandens and NSAIDs 
by calculating mean difference. 
Results 
From 42 articles identified, 4 studies involving a total of 414 patients were included for 
efficacy analysis. The effects of oral D. scandens on reducing pain score were no different 
from those of non-steroidal anti-inflammatory drugs at any time points (3, 7, 14 days and 
overall).  The overall pain reduction in the D. scandens group was not inferior to treatment 
with NSAIDs (weighted mean difference 0.06; 95% CI:-0.20, 0.31) without evident of 
heterogeneity (I2=0.00%, p=0.768). When compared, the adverse events (AEs) of D. 
scandens showed no different relative risk with NSAIDs. The major adverse events were 
gastrointestinal symptoms. 
Conclusion 
D. scandens may be considered as an alternative for musculoskeletal pain reduction. 
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Graphical abstract 
 
 
 
Abbreviations 
NLEMs, National List of Essential Medicines; NSAIDs, Nonsteroidal anti-inflammatory drugs 
(NSAIDs); COX-1, Cyclooxygenase 1; LTB4, Leukotriene-B4; AEs, Adverse events; RCT, 
Randomized controlled trial; PRISMA, Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses’ VAS, visual analog score; OA, Osteoarthritis; HPLC, High performance 
liquid chromatography 
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1. Introduction 
Derris scandens (Roxb.) Benth. (Fabaceae), Brachypterum scandens Benth. 
(synonym), Jewel vine or Thao-Wan-Priang (Thai name) is well–known medical plant in Asia 
and South East Asia. D. scandens stem or vine was traditionally used as a diuretic, 
antitussive, expectorant, antidysentery, and muscle pain treatment. It is also claimed as 
cancer prevention, and health promotion herb in cardiovascular patients and 
postmenopausal women (Sriwanthana and Chavalittumrong, 2001; Kuptniratsaikul et al., 
2011). 
 D. scandens dried powder (dose 0.5-1 g immediately after meal three times a day) 
and 50% hydroethanolic extract (dose 400 mg immediately after meal two times a day) were 
included in the List of Herbal Medicinal Products in the Thailand National List of Essential 
Medicines for musculoskeletal pain treatment (National drug committee, 2015, 
www.nlem.in.th). Active ingredients of D. scandens for anti-inflammatory effect are 
genisteinglycoside derivatives (isoflavones). The major active substance of antioxidant and 
anti-inflammation is genistein-7-O-[-rhamnopyranosyl-(16)--glucopyranoside] 
(Laupattarakasem et al., 2003; Kuptniratsaikul et al., 2011; Wongsinkongman et al., 2013). 
D. scandens extract exhibited good anti-inflammatory effect by inhibition of cyclooxygenase 
1 (COX-1) and leukotriene-B4 (LTB4) generation, reduction of eicosanoid synthesis via both 
cyclooxygenase and lipoxygenase pathways and myeloperoxide release (Wongsinkongman 
et al., 2013; Kuptniratsaikul et al., 2011; Mahabusarakam et al., 2004; Laupattarakasem et 
al., 2004). 
Musculoskeletal pain is a major medical problem commonly found in all countries 
(Mense, 2008; Hong, 2002). It is caused by the activation of nociceptive receptors leading to 
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releasing important endogenous inflammatory mediators such as prostaglandin E2. This 
mediator is important to produce local oedema, inflammation, and pain (Mense, 2008; Hong, 
2002; Basbuam and Jessell, 2000). Currently, nonsteroidal anti-inflammatory drugs 
(NSAIDs) which block prostaglandin synthesis are most commonly used for the treatment of 
musculoskeletal pain (Mense, 2008; Galer, 2001). However, causes of many adverse events 
such as gastrointestinal ulcer, allergy, heart failure and renal failure limit the use of NSAIDs. 
D. scandens has become a potentially viable option for pain management, since a number of 
research studies have evaluated the effects of D. scandensin a variety of clinical conditions 
especially for the treatment of musculoskeletal pain.  However, there remains a gap in the 
literature with no summarization of evidence on the clinical benefits and safety of D. 
scandens for pain management.  Although, there has been systematic reviews that provide 
evidence on oral herbal therapies for treating osteoarthritis, such as Boswellia serrata and 
avocado-soya bean unsaponifiables, the use of D. scandens has not been evaluated 
(Cameron and Chrubasik, 2014). The objective of this study is therefore to systematically 
review the literatures and conduct a meta-analysis to determine the efficacy and safety of 
oral D. scandens on pain management compared with NSAIDs. 
2. Methods 
This systematic review was conducted according to the Cochrane Collaboration 
framework guidelines(Higgins and Green; 2011),and was reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 
(Moher et al., 2009). 
2.1 Search strategies and study selection 
The following databases were used to search for original research articles from 
inception to December 2015: AMED, CINAHL, Cochrane Central Register of clinical trial, 
EMBASE, Health Science Journals in Thailand, PubMed, Thai Index Medicus, Thai Library 
Integrated System, Thai Medical Index, Thai Thesis Database, WHO registry, and 
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www.clinicaltrial.gov.  Strategic search terms used were Derris scandens OR Jewel vine OR 
Hog creeper OR Malay jewel vine OR “Thao-Wan-Priang” OR etc. For other sources, online 
and offline sources such as Journal of Thai Traditional & Alternative Medicine, libraries and 
references of papers derived for full text review were scanned to identify potential studies not 
indexed in the above databases.  The experts were also contacted for additional trials. 
Research articles were included if they met the following inclusion criteria: 1) 
randomized controlled trial (RCT) in patients with musculoskeletal pain and 2) evaluating 
clinical effects and/or safety of D. scandens for pain reduction treatment. There was no 
language restriction. PP scanned all the titles and abstracts to determine whether the studies 
assessed the effects of D. scandens.  Full-text articles of the potential studies were 
subsequently assessed by PP and RS. Disagreements and uncertainties regarding eligibility 
were resolved by discussions with NC, when necessary. 
2.2 Data extraction and quality assessment  
Data extraction was undertaken by PP and RS using a data extraction form in 
accordance with the CONSORT statement for reporting herbal medicinal interventions 
(Gagnier et al., 2006). The data extracted included: study design; number of participants; 
age of participants; pain score of participants; characteristics of the intervention; and 
outcome measurement. The outcome measure is pain score at the end of the studies.  
Studies included in this review were assessed for methodological quality by PP and RS 
using the Cochrane risk of bias tool (Higgins and Green; 2011), and JADAD score (Jadad et 
al., 1996). The Cochrane risk of bias evaluates bias in intervention studies based on a 
number of criteria including: sequence generation; allocation concealment; blinding; 
incomplete outcome data; selective reporting; and other sources of bias. Studies in which 
baseline characteristics were different among studies groups were considered as high risk 
for the domain of ‘other risk of bias’.  Each study was classified as having low risk (low risk of 
bias for all key domains), high risk (high risk of bias for one or more key domains), or unclear 
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risk (unclear risk of bias for one or more key domains). Overall JADAD score of 3 or 3 
indicates low or high methodological quality, respectively. Disagreements between the 
reviewers were settled through discussion and consensus.  
2.3 Statistical analysis 
Data from all studies were pooled in a meta-analysis to determine the overall effect 
size with 95% confidence interval.  Pooled effects were calculated and stratified according to 
indications of D. scandens and its comparators (NSAIDs). Mean of the outcome at variables 
time for each treatment arm were calculated.  Pooled standard deviations (Spooled) of the 
mean were used.  Then mean of the outcome variables were compared between 
intervention and comparator arms by calculating the overall mean differences, which could 
be weighted mean difference (WMD) for visual analog pain score.  For pain reduction 
indication, the weighted mean difference value above 0 indicated that D. scandens was less 
effective in reducing pain or alleviating difficulties in performing activities compared to 
comparators (NSAIDs).   
Statistical heterogeneity between studies was assessed using the chi-squared test 
and I2 (Higgins et al., 2003). Thresholds of I2 were interpreted in accordance with the 
magnitude and direction of effects and strength of evidence of heterogeneity (eg. p-value) as 
follows: might not be important (0%-30%); moderate heterogeneity (30%-50%); substantial 
heterogeneity (50%-75%); and considerable heterogeneity (75%-100%) (Higgins and Green, 
2011). The Dersimonian and Laird random-effects model was employed for all analyses 
(Dersimonian and Laird, 1986). Meta-analyses were conducted using STATA version 11 
(STATA Corp, College Station, TX, USA).  We also calculated the sample size required for 
testing non-inferiority between D. scandens and NSAIDs (Zhong, 2009) to determine 
whether the studies were of sufficient power to demonstrate non-inferiority. The non-
inferiority was tested with marginal difference of pain score of ± 1 score out of 10 scores of 
VAS based on previous study (Kuptniratsaikul et al., 2011). 
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3. Results 
3.1 Study selection 
Of the 42 articles found from the various databases searched and 7 articles identified 
through other sources (reference lists of retrieved articles or contact content expert for 
additional articles), 49 articles were eligible for screening after duplication removal.  Based 
on title and abstract screened, 8 articles were selected for full text review.  Four articles were 
excluded as two studies were not clinical studies and another two studies were safety 
studies in healthy volunteers. Four randomized controlled trials which involved a total of 414 
patients were included in this systematic review and meta-analysis (Fig. 1). 
3.2 Study characteristics  
Information extracted from the included studies was generally complied with the 
requirement in the CONSORT statement for reporting herbal medicinal interventions. All four 
RCTs (Table 1) were conducted in Thailand to investigate the effects of oral D. scandens on 
musculoskeletal pain reduction compared with NSAIDs. All of included articles reported Latin 
binomial of ingredient herbs. Method of authentication of raw material was also reported in 2 
studies (Srimongkol et al., 2007; Kuptniratsaikul et al., 2010). Only one study explained 
quantitative description and quantitative testing of D. scandens and presented sample size 
calculation for non-inferiority (Kuptniratsaikul et al., 2010). Duration of studies of all RCTs 
ranged from 7 to 28 days. 
The included studies were conducted in patients with primary osteoarthritis (OA) of 
knees (Kuptniratsaikul et al., 2010; Benchakanta et al., 2012), low back pain (Srimongkol et 
al., 2007) and chronic arthralgiafrom chikungunya (Maneenual et al., 2010) (Table 2). All 
patients were diagnosed by a medical doctor and confirmed by some laboratory test. 
Patients aged over 50 years were specified as the subjects of investigation in one study 
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(Kuptniratsaikul et al., 2010).The age of subjects in the remaining studies were ranged from 
18-60 years (Srimongkol et al., 2007;Maneenual et al., 2010;Benchakanta et al., 2012). The 
pain duration before entering the trial was reported in 3 studies ranging from less than 30 
days (acute pain) (Benchakanta et al., 2012) to 40 months (chronic pain) (Kuptniratsaikul et 
al., 2010).  
D. scandens dried powder and hydroethanolic extract (reflux using 50% ethanol in 
water) of D. scandens in capsule were used as intervention in the different dose and dosage 
forms. Two studies used 1,500 mg/day (Maneenual et al., 2010) and 3,000 mg/day 
(Benchakanta et al., 2012) of D. scandens dried powder while another two studies used 600 
mg/day (Srimongkol et al., 2007) and 800 mg/day (Kuptniratsaikul et al., 2010) of 
hydroethanolic D. scandens extract. All D. scandens preparations were prepared following 
the NLEM recommendation. The dose regimens used in 3 RCTs (Maneenual et al., 2010; 
Kuptniratsaikul et al., 2010; Benchakanta et al., 2012) were aligned with the recommended 
dose of D. scandens dried powder (1,500-3,000 mg/day) and hydroethanolic extract (800 
mg/day) in the NLEM (National drug committee, 2015, www.nlem.in.th). One study used D. 
scandens hydroethanolic extract lower than the recommendation dose in NLEM (Srimongkol 
et al., 2007). Two RCTs stated that hydroethanolic extract were standardized extract using 
genistein-7-O-[-rhamnopyranosyl-(16)-β-glucopyranoside] (Srimongkol et al., 2007; 
Kuptniratsaikul et al., 2010) as bioactive marker but no study reported the amount of 
standard reference in the extract or dried powder. The comparators of all included RCTs 
were NSAIDs including diclofenac 75 mg/day(Srimongkol et al., 2007; Maneenual et al., 
2010), naproxen 500 mg/day (Kuptniratsaikul et al., 2010) and ibuprofen 1,200 mg/day 
(Benchakanta et al., 2012)(Table 1). 
All included studies measured VAS of pain in the similar rating scale, 0 to 10, at 
different time points (Table 2). Two studies evaluated VAS of pain at 0, 3 and 7 days 
(Srimongkol, 2007; Benchakanta, 2012).In chronic pain studies, VAS of pain was measured 
at 0, 14 days (Maneenual et al., 2010), and at 0, 14 and 28 days, respectively 
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(Kuptniratsaikul et al., 2010). Zero score of VAS represents no pain whereas 10 score 
represents the worst pain. A higher score indicates greater pain intensity. The average 
baseline VAS of pain (mean±SD) in all included studies varied from 4.90±1.72 (Maneenual, 
2010) to 6.56±0.91 (Srimongkol, 2007). These scores were categorized as moderate pain 
(Jones, 2007). 
3.3 Quality of included studies 
Based on Cochrane’s risk of bias criteria, all of included studies were rated high risk 
of bias. All RCTs were rated high risk of bias in blinding domain because they used different 
dosage forms for intervention and comparator. Two studies were rated high risk of bias in 
sequence generation and allocation concealment domains (Maneenual et al., 2010; 
Benchakanta et al., 2012) because they used inappropriate method for randomization and 
allocation concealment. None of included studies showed bias in incomplete outcome data, 
selective outcome reporting and other sources of bias. JADAD score of all included studies 
was also examined. The methodological quality of included trials was low to medium with 
JADAD score ranging from 1 to 3 of a total score of 5 (Table 3).  
3.4 Clinical effects of D. scandens on musculoskeletal pain reduction 
All included RCT studies investigated the use of D. scandens or NSAIDs in patients 
with musculoskeletal pain, by measuring the level of pain using a visual analogue scale 
(VAS) of pain (Appendix 1). Based on meta-analysis using WMD of VAS of pain at the end 
of study, the pain level in subjects receiving D. scandens for musculoskeletal pain treatment 
was not statistically different from that of NSAIDs (WMD 0.06; 95% CI -0.20, 0.31) (Fig. 2).  
In subgroup analysis, no significant difference was identified for the effect of D. scandens on 
pain reduction when compared with NSAIDs at day 3 (WMD, 0.13; 95%CI -0.34, 0.59), day 7 
(WMD, 0.06; 95%CI -0.38, 0.50), and day 14 (WMD, 0.28; 95%CI -0.02, 0.58). Form 285 OA 
knee patients group, D. scandens exhibited non-inferiority for reducing VAS of pain to 
NSAIDs group (WMD 0.21; 95%CI -0.06, 0.48). Furthermore, D. scandens also alleviated 
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VAS of pain not lower than diclofenac 75 mg/day (WMD 0.22; 95%CI -0.41, 0.84) (Table 4). 
All meta-analysis results provided very low heterogeneity across studies (I2=0.00%). The 
very low heterogeneity supported the consistency effect of D. scandens compared with 
NSAIDs between all included studies. 
3.5 Adverse effects of D. scandens 
Safety outcomes of D. scandens compared with NSAIDs were reported in 3 studies 
(Kuptniratsaikul et al., 2010; Maneenual et al., 2010; Benchakanta et al., 2012). No serious 
adverse events were reported in any of the studies. There was no significant different risk 
ratio (pooled effect) of adverse events from ether group (Table 5). Kuptniratsaikul V, et al 
reported that dyspepsia and GI irritation events in naproxene group were higher than those 
in D. scandensgroup (Kuptniratsaikul et al., 2010). On the other hand, Benchakanta S, et al 
reported GI irritation events in ibuprofen group were lower than those inD. scandensgroup 
(Benchakanta et al., 2012).The major adverse events were gastrointestinal (GI) symptoms 
such as dyspepsia, GI irritation, constipation, andnausea/vomiting (Table 5). Central nervous 
system (CNS) and others adverse symptoms were also reported from D. scandens and 
comparator groups.  
4. Discussion 
 This systematic review and meta-analysis provides the efficacy of D. scandens arm 
in musculoskeletal pain were not inferior to that of standard drugs (NSAIDs) in all 
musculoskeletal pain patients at the end of each study and among knee OA patients. 
Furthermore, adverse events among patients using D. scandens and NSAIDs in a 
short period were comparable. The result showed the same rate of adverse events including 
gastrointestinal, central nerves system and others symptoms in both group. Normally, people 
usually use herbal medicine instead of chemical drug to avoid the adverse event or 
complication but the uses of D. scandens in a short period show similar adverse events of 
NSAIDs especially for gastrointestinal complications. Since previous in vivo and in vitro 
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studies reported that both D. scandens and NSAIDs can inhibit cyclooxygenase 1 (COX-1) 
and leukotriene-B4 (LTB4) generation in the same manner, similar AEs of both can be 
produced (Wongsinkongman et al., 2013; Kuptniratsaikul et al., 2011; Mahabusarakam et 
al., 2004; Laupattarakasem et al., 2004). In Thailand National List of Essential Medicines 
(NLEMs), D. scandens should be used with caution in peptic ulcer patients because it may 
irritate the gastrointestinal mucosa. D. scandens is also prohibited in pregnant females. 
From our results, the combination of D. scandens with NSAIDs which usually prescribed in 
Thailand hospital for musculoskeletal pain should be avoided due to their AEs. 
Although this study reveals that efficacy and safety D. scandens and NSAIDs for 
musculoskeletal pain seem similar. We suggest D. scandens as an alternative option of 
NSAIDs for musculoskeletal pain because D. scandens is Thai traditional medicine that is 
promoted to be used by Thai government. This herbal medicine can be produced by Thai 
company or hospital without any require imported chemical like NSAIDs. It results in 
stimulation of Thai economy and most of Thai people have easy access to this medicine. 
Moreover, NSAIDs have more other adverse effects such as increase risk of hypertension, 
cardiovascular diseases and kidney disease while these effects were not reported in the use 
of D. scandens (Kuptniratsaikul et al., 2010; Benchakanta et al., 2012; Srimongkol et al., 
2007; Maneenual et al., 2010; Chavalittumrong et al., 2008; Sriwathana et al., 2009). In 
addition, for long-term study we found that dyspepsia and GI irritation events of NSAIDs 
were higher than those of D. scandens (Kuptniratsaikul et al., 2010). Therefore, we believe 
that D. scandens may be safer than NSAIDs in long-term use or when concerned about 
other adverse events. 
The strength of our study is that it is a comprehensive summary of herbal medicine 
by using systematic reviews and meta-analyses which is at the top in the hierarchy of the 
clinical evidence and can answer the non-inferiority question. This study is one of a few 
systematic review and meta-analysis studies conducted in the field of complementary and 
alternative medicine (Schneider et al., 2005). The non-inferiority question is appropriate and 
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relevant for this context since the usual care is active comparator rather than placebo. The 
comparison of an herbal product to active comparator is very justified. 
Even though the evidence on pain reduction is quite consistent across studies and 
non-inferior the effect of NSAIDs, a number of limitations should be mentioned.  First, 
standardization method and bioactive marker content in herbal products including D. 
scandens preparations are very important step for clinical evaluation of herbal medicines 
(Gagnier et al., 2006). Since active ingredients in herbal products are influenced by several 
factors such as place, season or preparation, this may result in different clinical effects 
(Puttarak and Panichayupakaranant, 2012). All of included studies did not report amount of 
active compound in D. scandens preparations which may also be a limitation of this study 
and may lead to different of clinical outcomes. To ensure the quality of products, Genistein-
7-O-[-rhamnopyranosyl-(16)--glucopyranoside](a flavonoid compound as anti-
inflammatory and analgesic activity) should be used as a biomarker compound in 
hydroalcoholic extract or dry powder of D. scandens.  Second, there are no data about dose 
response effect of D. scandens for pain reduction especially for dose of active constituents 
or standardized extract. Dose of standardized D. scandens is needed and should be  
investigated in future studies for the proper use of D. scandens. Third, the low quality of all 
included studies, because they did not employ a suitable randomization, concealment 
approach and blinding. However, this study provides current evidence based medicine of D. 
scandens on musculoskeletal pain by using systematic review and meta-analysis according 
to PRISMA guideline which is a widely acceptable method for drawing conclusions of clinical 
evidence of interventions. Therefore, taking into account the relatively low quality of included 
studies, caution should be made when interpreting or applying the results derived from these 
studies. Futures RCTs should be conducted as high quality trials and report according to 
CONSORT.  
5. Conclusion 
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Current evidence suggested that D. scandens might be considered as a potential 
alternative for NSAIDs for the treatment of musculoskeletal pain since its use, as traditional 
medicine and listed product in NLEM. The use of D. scandens as alternative medicine could 
support local economy system in Thailand and it might be safer than NSAIDs in long-term 
use. Concomitant use of D. scandens and NSAIDs, should be avoided due to their similar 
AEs. However, given that the overall quality of current studies is low with short period of 
follow-up, firm conclusions on the efficacy and safety of D. scandens cannot be drawn. 
Interpretation of current evidence should be done with caution and further studies with higher 
quality remain needed. In addition, dose response effect and long-term use of standardized 
D. scandens products should be further investigated. 
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Figure 1 Flow diagram of study selection 
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Figure 2 Efficacy comparisons of Derris scandens (Roxb.) Benth. and NSAIDs for pain 
reduction at end of study 
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Table1 Characteristics of Derris scandens (Roxb.) Benth. in included studies 
Author 
Plant 
part 
Preparation Extraction method Standardization 
Dose/day 
(mg) 
Standard 
compound 
Srimongkol, 2007 Vine Extract 
Reflux method 
using 50% ethanol 
Yes 600 Genistein* 
Kuptniratsaikul, 2010 Stem Extract 
Reflux method 
using 50% ethanol 
Yes 800 Genistein* 
Maneenual, 2010 Vine Dry powder N/A No 1,500 NR 
Benchakanta, 2012 Vine Dry powder N/A No 3,000 NR 
N/A = Not applicable, NR = not report, * genistein-7-O-[-rhamnopyranosyl-(16)-β-glucopyranoside] 
 
 
 
Table 2 Characteristics of included studies  
Author 
RCTs 
meth
od 
Patient
s 
Groups 
No. 
Patien
ts 
Pain 
durati
on 
(mont
hs) 
Mean 
age; or 
[Range
] 
(Years) 
Treatm
ent 
duratio
n 
(Days) 
M:F BMI 
Baselin
e pain 
score 
Srimongk
ol, 2007 
Doubl
e  
blind 
Low 
back  
pain 
D. scandens 200 
mg TID 
Diclofenac 25 mg 
TID 
37 
33 
NR 
NR; 
[20-60] 
7 
5:32 
6:27 
No 
overwe
ight 
6.41±1.
12 
6.56±0.
91 
Kuptnirat
saikul, 
2010 
Open  
label 
Primary 
OA  
knee  
D. scandens 400 
mg BID 
Naproxen 250 
mg BID 
63 
62 
39.8±4
9.3 
36.2±3
4.5 
59.4±7.
0 
60.5±8.
2 
28 
8:47 
10:4
2 
26.3±3
.8 
26.6±3
.6 
5.10±1.
40 
5.60±1.
70 
Maneenu
al, 2010 
Doubl
e  
blind 
Chronic  
arthralgi
a* 
D. scandens 500 
mg TID 
Diclofenac 25 mg 
TID 
29 
30 
 12 
NR; 
[18-60] 
14 
1:28 
5:25 
NR 
4.90±1.
72 
5.03±1.
63 
Benchak
anta, 
2012 
Doubl
e  
blind 
Primary 
OA  
knee  
D. 
scandens1,000 
mg TID 
Ibuprofen 400 
mg TID 
94 
94 
 1 
48.1±7.
8 
49.2±7.
2 
7 
15:7
3 
17:7
3 
25.5±4
.0 
25.6±3
.5 
4.92±1.
97 
4.99±1.
84 
RCT = Randomized controlled trials, NR = Not report, *Chikungunya patients (positive: 
antibody IgM) with fever 4 days 
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Table 3 Methodological quality assessment of the included studies 
Author 
Risk of bias domain 
JADA
D 
Score 
Sequen
ce 
generati
on 
Allocatio
n 
conceal
ment 
Blinding Incomple
te 
outcome 
data 
Selective 
outcome 
reporting 
Other 
sources 
of bias 
Overall 
risk of 
bias 
Investig
ator 
Patient 
Srimongkol, 
2007 
L U U H L L L H 3 
Kuptniratsaik
ul, 2010 
L U L H L L L H 3 
Maneenual, 
2010 
H H U H L L L H 1 
Benchakanta
, 2012 
H H L H L L L H 1 
L = Low risk, U = Unclear, H = High risk 
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Table 4 Subgroup analysis results of Derris scandens (Roxb.) Benth. compared with 
NSAIDs  
Study N 
Mean difference 
[95% Confident interval] 
p-value 
Heterogeneity test 
% I
2
 
X
2
 p-value 
Efficacy at various time point 
Srimongkol, 2007 70 0.35 [-0.46, 1.16]     
Benchakanta, 2012 178 0.02 [-0.54, 0.58]     
Pool effect at 3 days 248 0.13 [-0.34, 0.59] 0.593 0.43 0.513 0.00 
Srimongkol, 2007 70 -0.02 [-0.84, 0.80]     
Benchakanta, 2012 178 0.09 [-0.43, 0.61]     
Pool effect at 7 days 248 0.06 [-0.38, 0.50] 0.794 0.05 0.825 0.00 
Kuptniratsaikul, 2010 107 0.25 [-0.06, 0.56]     
Maneenual, 2010 59 0.54 [-0.42, 1.50]     
Pool effect at 14 days 166 0.28 [-0.02, 0.58] 0.068 0.32 0.574 0.00 
Effect on primary OA knee pain 
Kuptniratsaikul, 2010 107 0.25 [-0.06, 0.56]     
Benchakanta, 2012 178 0.09 [-0.43, 0.61]     
Pool effect  285 0.21 [-0.06, 0.48] 0.130 0.27 0.606 0.00 
Effect of D. scandenscomparewithdiclofenac (75 mg/day) 
Srimongkol, 2007 70 -0.02 [-0.84, 0.80]     
Maneenual, 2010 59 0.54 [-0.42, 1.50]     
Pool effect  129 0.22 [-0.41, 0.84] 0.497 0.75 0.386 0.00 
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Table5 Adverse events (AEs) of Derris scandens (Roxb.) Benth. compared with 
NSAIDs 
Adverse events Study 
Total events/group (%) Risk ratio 
(95% CI) 
I
2
 
(%) D. scandens NSAIDs 
Overall AEs 
 Benchakanta, 2012 32/90 (35.55) 35/88 (39.77) 0.85 (0.61, 1.31)  
 Kuptniratsaikul, 2010 22/63 (34.9) 29/62 (46.8) 0.75 (0.49, 1.15)  
   0.83 (0.62, 1.10) 0.0 
Gastrointestinal (GI) symptoms 
Dyspepsia Benchakanta, 2012 12/90 (13.33) 5/88 (5.68) 2.35 (0.86, 6.39)  
 Kuptniratsaikul, 2010 3/63 (4.80) 18/62 (29.0) 0.16 (0.05, 0.53)  
 Maneenual, 2010 2/29 (3.33) 3/30 (0.00) 0.69 (0.12, 3.83)  
    0.65 (0.11, 3.79) 82.8 
GI irritation Benchakanta, 2012 15/90 (16.67) 5/88 (5.68) 2.93 (1.11, 7.73)  
 Kuptniratsaikul, 2010 2/63 (3.20) 14/62 (22.6) 0.14 (0.03, 0.59)  
    0.67 (0.03, 13.88) 91.8 
Nausea Benchakanta, 2012 2/90 (2.22) 1/88 (1.14) 1.96 (0.18, 21.18)  
 Kuptniratsaikul, 2010 1/63 (1.60) 1/62 (1.60) 0.96 (0.66, 15.39)  
    1.46 (0.24, 8.82) 0.0 
Vomiting Benchakanta, 2012 0/90 (0.00) 1/88 (1.14) 0.33 (0.01, 7.90)  
 Kuptniratsaikul, 2010 0/63 (0.00) 1/62 (1.60) 0.33 (0.01, 7.90)  
    0.33 (0.03, 3.11) 0.0 
Flatulence Benchakanta, 2012 4/90 (4.44) 4/88 (4.54) 0.98 (0.25, 3.79)  
 Maneenual, 2010 4/29 (13.8) 0/30 (0.00) 9.30 (0.52, 165.4)  
    2.14 (0.24, 18.96) 51.9 
Constipation Benchakanta, 2012 4/90 (4.44) 1/88 (1.14) 3.91 (0.45, 34.31)  
 Kuptniratsaikul, 2010 2/63 (3.20) 1/62 (1.60) 1.97 (0.18, 21.15)  
 Maneenual, 2010 4/29 (13.8) 0/30 (0.00) 9.30 (0.52, 165.4)  
    3.78 (0.93, 15.34) 0.0 
Loose stool Kuptniratsaikul, 2010 3/63 (4.80) 2/62 (3.20) 1.48 (0.26, 8.52) - 
Melena Kuptniratsaikul, 2010 0/63 (0.00) 1/62 (1.60) 0.33 (0.01, 7.90) - 
Dry mouth/throat Maneenual, 2010 1/29 (3.45) 1/30 (3.33) 1.03 (0.07, 15.77) - 
Central nerves system (CNS)symptoms 
Dizziness Benchakanta, 2012 5/90 (5.55) 7/88 (7.95) 0.70 (0.23, 2.12)  
 Maneenual, 2010 1/29(3.45) 5/30 (16.67) 1.48 (0.44, 4.98)  
 Kuptniratsaikul, 2010 6/63 (9.50) 4/62 (6.50) 0.21 (0.03, 1.67)  
    0.76 (0.31, 1.90) 25.4 
Headache Benchakanta, 2012 7/90 (7.78) 5/88 (5.68) 1.37 (0.45, 4.15)  
 Maneenual, 2010 1/29(3.45) 5/30 (16.67) 1.48 (0.26, 8.53)  
 Kuptniratsaikul, 2010 3/63 (4.80) 2/62 (3.20) 0.21 (0.03, 1.67)  
    0.94 (0.32, 2.71) 27.3 
Drowsiness Benchakanta, 2012 9/90 (10.00) 10/88 (11.36) 0.88 (0.38, 2.06) - 
Others symptoms 
Appetite increased Benchakanta, 2012 4/90 (4.44) 1/88 (1.14) 3.91 (0.45, 34.31) - 
Sweating Benchakanta, 2012 4/90 (4.44) 3/88 (3.41) 1.30 (0.30, 5.66) - 
Rash Kuptniratsaikul, 2010 2/63 (3.20) 1/62 (1.60) 1.97 (0.18, 21.15) - 
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Appendix 1 Outcomes 
Author Treatment 
VAS of pain score (Mean±SD) 
Day 0 Day 3 Day 7 Day 14 Day 28 
Srimongkol, 
2007 
D. scandens 6.41±1.12 3.41±1.38 1.73±1.43 N/A N/A 
Diclofenac 6.56±0.91 3.06±2.00 1.75±2.00 N/A N/A 
Kuptniratsaikul, 
2010 
D. scandens 5.10±1.40 N/A N/A 3.75±0.80 3.35±0.80 
Naproxen 5.60±1.70 N/A N/A 3.50±0.85 3.35±0.90 
Maneenual, 
2010 
D. scandens 4.90±1.72 N/A N/A 2.21±1.99 N/A 
Diclofenac 5.03±1.63 N/A N/A 1.67±1.77 N/A 
Benchakanta, 
2012 
D. scandens 4.92±1.97 3.71±1.84 2.63±1.73 N/A N/A 
Ibuprofen 4.99±1.84 3.69±1.96 2.53±1.81 N/A N/A 
N/A = Not applicable 
